GSK said on Monday it had entered into a strategic collaboration with Hong Kong-listed Sino Biopharmaceutical (1177) to accelerate the launch of its hepatitis B treatment bepirovirsen in mainland China.
Under the agreement, GSK's second deal with a Chinese pharmaceutical group after a US$500 million deal with Jiangsu Hengrui (1276) to develop up to a dozen new medicines, Sino's unit Chia Tai Tianqing Pharmaceutical (CTTQ) will purchase bepirovirsen from GSK for an initial term of five and a half years, which is extendable by mutual agreement.
Bepirovirsen is GSK's experimental drug designed to tackle hepatitis B in three ways: by blocking viral DNA replication, lowering hepatitis B surface antigen levels in the blood, and boosting the immune response to help achieve longer-lasting control of the disease.
Reuters
𝗗𝗼𝘄𝗻𝗹𝗼𝗮𝗱 𝗧𝗵𝗲 𝗦𝘁𝗮𝗻𝗱𝗮𝗿𝗱 𝗔𝗽𝗽 ↓
